Table 1.
Unadjusted Patient and Tumor Characteristics by pathological nodal status, NCDB 2006–2011
| pN0 Disease | pN+ Disease | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall | Adjuvant Chemo (n = 15) | Surgery alone (n = 348) | P-value | Overall | Adjuvant Chemo (n = 89) | Surgery alone (n = 129) | P-value | |
| Patient characteristics | ||||||||
| Age, yrs (IQR) | 61 (53, 69) | 61 (53.5, 70) | 61 (53, 69) | 0.98 | 62 (52, 71) | 57 (50, 69) | 63 (55, 72) | 0.006 |
| Female | 219 (60.3%) | 6 (40%) | 213 (61.2%) | 0.17 | 146 (67%) | 55 (61.8%) | 91 (70.5%) | 0.23 |
| Race | 0.71 | 0.53 | ||||||
| White | 314 (88%) | 14 (93.3%) | 300 (87.7%) | 194 (89.8%) | 80 (92%) | 114 (88.4%) | ||
| Black | 30 (8.4%) | 1 (6.7%) | 29 (8.5%) | 22 (10.2%) | 7 (8%) | 15 (11.6%) | ||
| Other | 13 (3.6%) | 0 (0%) | 13 (3.8%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Charlson-Deyo Score | 0.57 | 0.05 | ||||||
| 0 | 228 (62.8%) | 8 (53.3%) | 220 (63.2%) | 143 (65.6%) | 66 (74.2%) | 77 (59.7%) | ||
| 1 | 102 (28.1%) | 6 (40%) | 96 (27.6%) | 56 (25.7%) | 19 (21.3%) | 37 (28.7%) | ||
| ≥2 | 33 (9.1%) | 1 (6.7%) | 32 (9.2%) | 19 (8.7%) | 4 (4.5%) | 15 (11.6%) | ||
| Education census tract | 0.5 | 0.88 | ||||||
| Bottom | 52 (14.6%) | 2 (13.3%) | 50 (14.7%) | 31 (14.3%) | 11 (12.4%) | 20 (15.6%) | ||
| Second | 87 (24.5%) | 6 (40%) | 81 (23.8%) | 47 (21.7%) | 21 (23.6%) | 26 (20.3%) | ||
| Third | 131 (36.9%) | 5 (33.3%) | 126 (37.1%) | 92 (42.4%) | 38 (42.7%) | 54 (42.2%) | ||
| Top | 85 (23.9%) | 2 (13.3%) | 83 (24.4%) | 47 (21.7%) | 19 (21.3%) | 28 (21.9%) | ||
| Income census tract | 0.84 | 0.7 | ||||||
| Bottom | 48 (13.5%) | 3 (20%) | 45 (13.2%) | 29 (13.4%) | 10 (11.2%) | 19 (14.8%) | ||
| Second | 86 (24.2%) | 4 (26.7%) | 82 (24.1%) | 46 (21.2%) | 21 (23.6%) | 25 (19.5%) | ||
| Third | 96 (27%) | 4 (26.7%) | 92 (27.1%) | 76 (35%) | 29 (32.6%) | 47 (36.7%) | ||
| Top | 125 (35.2%) | 4 (26.7%) | 121 (35.6%) | 66 (30.4%) | 29 (32.6%) | 37 (28.9%) | ||
| Insurance status | 0.61 | 0.05 | ||||||
| Private | 184 (50.7%) | 7 (46.7%) | 177 (50.9%) | 104 (47.7%) | 50 (56.2%) | 54 (41.9%) | ||
| Medicare/Medicaid | 160 (44.1%) | 6 (40%) | 154 (44.3%) | 107 (49.1%) | 34 (38.2%) | 73 (56.6%) | ||
| Other Government | 2 (0.6%) | 0 (0%) | 2 (0.6%) | 1 (0.5%) | 1 (1.1%) | 0 (0%) | ||
| Unknown | 8 (2.2%) | 1 (6.7%) | 7 (2%) | 2 (0.9%) | 1 (1.1%) | 1 (0.8%) | ||
| Uninsured | 9 (2.5%) | 1 (6.7%) | 8 (2.3%) | 4 (1.8%) | 3 (3.4%) | 1 (0.8%) | ||
| Tumor characteristics | ||||||||
| Tumor size (mm) | 22 (15, 34) | 30 (19, 45) | 22 (15, 32.2) | 0.08 | 30 (20, 36.8) | 27 (20, 35) | 30 (20, 40) | 0.38 |
| Pathologic stage | 0.72 | 0.31 | ||||||
| Stage 1 | 201 (92.6%) | 8 (100%) | 193 (92.3%) | 1 (0.7%) | 0 (0%) | 1 (1.2%) | ||
| Stage 2 | 14 (6.5%) | 0 (0%) | 14 (6.7%) | 79 (54.1%) | 30 (48.4%) | 49 (58.3%) | ||
| Stage 3 | 2 (0.9%) | 0 (0%) | 2 (1%) | 66 (45.2%) | 32 (51.6%) | 34 (40.5%) | ||
| Facility characteristics | ||||||||
| Distance traveled (miles, IQR) | 11.7 (4.8, 31.6) | 9.8 (4.4, 18.1) | 11.8 (4.9, 31.7) | 0.48 | 14 (5.2, 28.8) | 18 (7.8, 32.1) | 10.6 (4.6, 22.8) | 0.005 |
| Treatment facility | 0.56 | 0.64 | ||||||
| Community Program | 16 (4.4%) | 1 (6.7%) | 15 (4.3%) | 7 (3.2%) | 4 (4.5%) | 3 (2.3%) | ||
| Comprehensive Community Program | 169 (46.7%) | 5 (33.3%) | 164 (47.3%) | 115 (53%) | 45 (51.1%) | 70 (54.3%) | ||
| Academic Program | 177 (48.9%) | 9 (60%) | 168 (48.4%) | 95 (43.8%) | 39 (44.3%) | 56 (43.4%) | ||
Percentages have been rounded and may not add up to 100 %
NCDB National Cancer Data Base, pN0 pathologically node negative, pN+ pathologically node positive,
IQR Interquartile Range